Orchestra BioMed is a biomedical innovation company that develops late-stage clinical medical device candidates focused on treating major global health challenges, including uncontrolled hypertension and atherosclerotic artery disease. The company employs a partnership-enabled business model, conducting research and development on promising therapeutic solutions while strategic partners like Medtronic and Terumo handle commercialization, regulatory approval, manufacturing, and market distribution. Orchestra BioMed generates revenue through per-device payments, royalties, and revenue-sharing arrangements with its partners, optimizing capital efficiency by combining its R&D expertise with partners' established commercial infrastructure to bring novel treatments to large, established medical device markets.